相关实验视频
Updated: Jun 14, 2025

Self-Administration of Drugs in Mouse Models of Feeding and Obesity
Published on: June 8, 2021
里斯佩里颗粒,Pycnogenol®和Glucomannan Gummy配方用于管理自闭症儿童的体重增加和ADHD
Rawand M Daghmash1, Mai S Khanfar1, Ruba S Darweesh1
1Department of Pharmaceutical Technology, Faculty of Pharmacy, Jordan University of Science and Technology, P.O. Box 3030, Irbid 22110, Jordan.
这项研究为儿科开发了新的Risperidone药物,为患者提供了量身定制的,可控释放的剂量形式. 这些视觉上有吸引力的gummies解决了儿科药物管理中的挑战.
科学领域:
- 制药技术 制药技术 制药技术
- 儿科配方 儿科配方 儿科配方
- 药物输送系统 药物输送系统
背景情况:
- 里斯佩里是一种非典型的抗精神病药物,用于治疗精神分裂症和自闭症相关的烦躁症.
- 儿科患者经常面临传统口服药物的挑战.
- 药用口香糖为儿童提供了潜在的更可接受和有效的剂量形式.
研究的目的:
- 开发和表征新的Risperidone装载的药用口香糖用于儿科使用.
- 为了评估从口香糖配方中皮的可控释放性质.
- 评估制剂的适用性,以改善儿科药物服药.
主要方法:
- 使用Glucomannan和Gelatin开发了两个基.
- 装载基与涂层Risperidone颗粒,具有可控释放层.
- 物理性质 (pH,粘度) 和化学性质 (含量均性,药物含量,溶解概况) 的评估.
主要成果:
- 两种制剂 (F1和F2) 均表现出适当的质,并符合统一性标准.
- 酸性介质显示Risperidone释放有限 (25%为F1,11%为F2在2小时后).
- 在两种配方的pH值为6.8时,在24小时内观察到药物完全释放.
结论:
- 含有涂层Risperidone颗粒的可半固体制剂适用于儿科患者.
- 高胃抗性涂层颗粒可确保药物的适当释放,并可帮助克服儿科药物治疗的挑战.
- 这些新的片代表了对儿科Risperidone管理的有希望的替代方案.
更多相关视频
10:02Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD
Published on: March 12, 2020
07:05Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet
Published on: January 3, 2017
相关概念视频
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Antidepressant Drugs: MAOIs and Other Agents
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Drug Therapy
Antianxiety Medications